In Vivo Pharmacology Services
Translating science
from bench to model
Our in vivo capability encompasses study design, management and full PK/PD analysis through trusted external CRO partners. We work closely with our DMPK and cell biology teams to ensure seamless translation of in vitro data to in vivo studies, supporting confident progression decisions at every stage of the discovery process.
Translating in vitro to in vivo
From study design to bioanalysis and PK/PD reporting, we provide end-to-end in vivo support to bridge in vitro pharmacology with pre-clinical evidence.
Study Design
Expert design and management of outsourced in vivo studies through established CRO partnerships, aligned to project objectives and timelines.
- Design and management of outsourced efficacy, PK/PD and pharmacokinetic studies
- Selection and oversight of external CRO partners
- Dose formulation and dosing route optimisation
Bioanalysis
Comprehensive bioanalytical support for in vivo studies, covering sample processing through to quantitative pharmacokinetic reporting.
- Bioanalysis of plasma, tissue and other biofluids by LCMS-MS
- Tissue preparation and extraction for bioanalysis
- Plasma and tissue biomarkers for PK/PD assessment
PK/PD Analysis
Full pharmacokinetic evaluation and PK/PD analysis to extract maximum insight from in vivo studies and guide future compound design.
- Pharmacokinetic evaluation and comprehensive result reporting
- PK/PD analysis connecting compound exposure with pharmacological effect
- In vitro-in vivo correlation (IVIVC) to support prediction and design
Oncology Models
Extensive experience managing oncology in vivo models, from efficacy studies to mechanistic work supporting pre-clinical development.
- Management of xenograft and other tumour models through CRO partners
- Extensive oncology experience from hit ID to early pre-clinical development
- Biomarker development to support mechanism of action and PK/PD understanding
Integrated Drug Discovery
Turning discovery potential into clinical promise
Our in vivo capability bridges the gap between in vitro pharmacology and pre-clinical models — ensuring your compound’s performance is validated through expert study design, bioanalysis and PK/PD interpretation.
Biology Foundations
Structure & Hit ID
DEL Services
Chemistry & Data
Preclinical Readiness
Why work with us
Bridging in vitro science with pre-clinical evidence
Our in vivo pharmacology services are built on deep scientific expertise in study design, bioanalysis and PK/PD interpretation — not just outsourcing. We work closely with DMPK and cell biology teams to ensure that in vivo studies are designed for maximum insight and that data is interrogated rigorously to support progression decisions.
Contact us for more information.
In Vivo Case Studies
Explore how our in vivo services have delivered the pre-clinical evidence needed to progress novel compounds towards candidate selection.
-
Hsp90 oral backup pre-clinical candidate
Fragment-based and in silico hits were combined into a novel series of Hsp90 inhibitors, delivering tumour growth regression on oral dosing in a BT474 xenograft model.
Outcome Oral pre-clinical candidate — the follow-on to the intravenous phase II compound. -
DYRK1A and DYRK1B selective inhibitors
A Vernalis and Servier NMR fragment screen delivered two series of potent, selective DYRK1A inhibitors, including the brain-penetrant tool compound 34.
Outcome Two optimised inhibitor series and a selective, brain-penetrant tool compound.
Bring your compound to life in vivo
We’d love to hear from you! Head to our contact page to get started.